Versameb AG is a privately held company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression and cellular targeting. Versameb’s proprietary technology platform optimizes the application of functional mRNA in different disease contexts. The company is based in Basel, Switzerland and is fully operating since 2018.